Ypsomed announced plans to expand its offerings of digital health solutions for chronic disease therapy together with S3 Connected Health.
Dublin, Ireland-based S3 Connected Health specializes as a digital health partner for life science companies. This partnership allows Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. It enables therapy management support for acute and chronic diseases while enhancing outcomes.
Ypsomed said in a news release that the companies aim to create an extendable platform to create specific solutions. These offerings provide patients with support and guidance throughout therapy. Ypsomed’s connected injection devices, including the SmartPilot for YpsoMate, come pre-integrated into the platform.
The platform itself offers versatility and customization capabilities for any disease area and use case, the companies say.
“The new platform will enable our Pharma and Biotech customers to rapidly launch integrated device and digital health solutions that will further improve therapy outcomes and quality of life for their patients,” said Ulrike Bauer, Ypsomed chief business officer for delivery systems. “This new product offering complements our existing product portfolio and partnerships in the connected device and digital health area. It will help us to strengthen our position in this space and provide our customers with the best possible value.”
How Ypsomed and S3 Connected Health plan to combine offerings
S3 Connected Health’s Affinial platform powers the offering, encoding more than 20 years of best practice experience into digital health delivery.
The new platform from the companies includes a patient application, a clinical system and a patient support portal. Its analytical dashboard features real-time access to anonymized data.
With pre-integration into Ypsomed’s device portfolio, the platform offers a range of features around self-injection. It also incorporates behavioral science mechanisms to ensure high levels of engagement, plus personalization to patient needs.
“We look forward to collaborating closely with Ypsomed to achieve our shared vision of improving patients’ lives. Our Affinial platform and deep expertise in creating and operating regulated digital health solutions is a perfect fit with Ypsomed’s drive for innovation and highest quality,” said Jim O’Donoghue, President of S3 Connected Health.
The new product offering will be marketed through Ypsomed and will be offered to customers in collaboration with S3 Connected Health for customization to serve their specific use cases and brand.